Incidence of Malignancy and Risk Factors Associated with Kidney Transplant Patients
Malignancy with Kidney Transplant Patients
DOI:
https://doi.org/10.31661/gmj.v13i.3518Keywords:
Post-transplant Malignancy; Kidney Transplantation; Risk Factor; IncidenceAbstract
Background: The incidence and risk factors associated with the development of post-transplant malignancies contributes to increased morbidity among kidney transplant recipients were examined in this study. Materials and Methods: A retrospective cross-sectional analysis was conducted to evaluate the medical records of all kidney transplant recipients at Urmia Imam Khomeini Hospital from January 2000 to December 2020. Patients were stratified into two groups based on the presence or absence of post-transplant malignancy. Demographic data, comorbidities, cancer history, and immunosuppression regimens were collected and compared between the groups. Statistical significance was determined using appropriate tests. All analyses were performed using SPSS 21, and a P-value of less than 0.05 was considered statistically significant. Results: Of the 4070 kidney transplant recipients, 3042 (74.7%) were male and 1028 (25.3%) were female. The mean age at malignancy diagnosis was 53.78 years (standard deviation ± 14.24). The overall incidence of post-transplant malignancy was 9.6% per 1,000 patients (95% confidence interval: 9.6-13.2). Incidence rates varied significantly by age group: 4.6% for those younger than 30, 7.6% for those aged 30-50, and 29.3% for those older than 50 (P<0.001). A small percentage of patients (n=3, 7.7%) required the addition of antithymocyte globulin (ATG) to their primary immunosuppression regimen. The most commonly used immunosuppressive regimens were prednisolone in combination with either sandimune and azathioprine or sandimune and cellcept, employed in 35.9% of patients. The most common underlying causes of kidney failure were glomerulonephritis (GN) and hypertension (HTN), accounting for 38.5% and 35.9% of cases, respectively. Conclusion: Kidney transplant recipients demonstrated a higher incidence of post-transplant malignancies. Male sex, older recipient age, and a history of underlying diseases were identified as significant risk factors for malignancy development. The primary cause of kidney failure among the patients was GN, followed by HTN.
References
Jung SW, Lee H, Cha JM. Risk of malignancy in kidney transplant recipients: a nationwide population-based cohort study. BMC nephrology. 2022 Apr 28;23(1):160.
https://doi.org/10.1186/s12882-022-02796-6
Yoo KD, Kim CT, Kim MH, Noh J, Kim G, Kim H, An JN, Park JY, Cho H, Kim KH, Kim H, Ryu DR, Kim DK, Lim CS, Kim YS, Lee JP. Superior outcomes of kidney transplantation compared with dialysis: An optimal matched analysis of a national population-based cohort study between 2005 and 2008 in Korea. Medicine (Baltimore). 2016 Aug;95(33):e4352.
https://doi.org/10.1097/MD.0000000000004352
Van Sandwijk MS, Bemelman FJ, Ten Berge IJ. Immunosuppressive drugs after solid organ transplantation. Neth J Med. 2013 Jul 1;71(6):281-9.
Villanego F, Vigara LA, López V, de Gracia MD, Rodríguez-Benot A, Bernal G, et al. Changes over time in the causes of death with a functioning graft in kidney transplantation recipients. Nefrología (English Edition). 2023 Jan 1;43(1):91-101.
https://doi.org/10.1016/j.nefroe.2023.05.013
Jeong S, Lee HS, Kong SG, Kim DJ, Lee S, Park MJ, Song W, Rim JH, Kim HJ. Incidence of malignancy and related mortality after kidney transplantation: a nationwide, population-based cohort study in Korea. Sci Rep. 2020 Dec 8;10(1):21398.
https://doi.org/10.1038/s41598-020-78283-5
Massicotte-Azarniouch D, Noel JA, Knoll GA. Epidemiology of Cancer in Kidney Transplant Recipients. InSeminars in Nephrology. 2024;44(1):151494.
https://doi.org/10.1016/j.semnephrol.2024.151494
Fuhrmann JD, Valkova K, von Moos S, Wüthrich RP, Müller TF, Schachtner T. Cancer among kidney transplant recipients> 20 years after transplantation: post-transplant lymphoproliferative disorder remains the most common cancer type in the ultra long-term. Clinical Kidney Journal. 2022 Jun;15(6):1152-9.
https://doi.org/10.1093/ckj/sfac013
Minas TZ, Kiely M, Ajao A, Ambs S. An overview of cancer health disparities: new approaches and insights and why they matter. Carcinogenesis. 2021 Jan 1;42(1):2-13.
https://doi.org/10.1093/carcin/bgaa121
Manickavasagar R, Thuraisingham R. Post renal-transplant malignancy surveillance. Clinical Medicine. 2020 Mar;20(2):142.
https://doi.org/10.7861/clinmed.2019-0423
Krishnan A, Wong G, Teixeira-Pinto A, Lim WH. Incidence and Outcomes of Early Cancers After Kidney Transplantation. Transplant International. 2022;35:10024.
https://doi.org/10.3389/ti.2022.10024
Au EH, Chapman JR, Craig JC, et al. Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant. J Am SocNephrol. 2019; 30: 471-480.
https://doi.org/10.1681/ASN.2018090906
Boute TC, Swartjes H, Greuter MJE, Elferink MAG, van Eekelen R, Vink GR, de Wilt JHW, Coupé VMH. Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II-III Colorectal Cancer: A Population-based Study. Cancer Res Commun. 2024 Feb 29;4(2):607-616.
https://doi.org/10.1158/2767-9764.CRC-23-0512
Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. J Am SocNephrol. 2020;31(12):2887-99.
https://doi.org/10.1681/ASN.2020050566
Mazuecos A, Munoz Terol JM, Garcia Alvarez T, Sola E, Rodriguez Benot A, Dsuna A, Bedoya R, Gentil MA. Increase in malignancies as cause of death in renal transplant patients. Transpl Proc. 2009;41(6):2159-62.
https://doi.org/10.1016/j.transproceed.2009.05.029
Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J. 2015; 8: 637-644.
https://doi.org/10.1093/ckj/sfv054
Katabathina VS, Menias CO, Tammisetti VS, Lubner MG, Kielar A, Shaaban A, Mansour J, Surabhi VR, Hara AK. Malignancy after solid organ transplantation: comprehensive imaging review. Radiographics. 2016 Sep;36(5):1390-407.
https://doi.org/10.1148/rg.2016150175
Apel H, Walschburger-Zorn K, Häberle L, et al. De novo malignancies in renal transplant recipients:experience at a single center with 1882 transplant patients over 39 year. Clin Transplant. 2013;27:E30-6.
https://doi.org/10.1111/ctr.12050
Ietto G, Gritti M, Pettinato G, Carcano G, Gasperina DD. Tumors after kidney transplantation: a population study. World J SurgOncol. 2023 Jan 23;21(1):18.
https://doi.org/10.1186/s12957-023-02892-3
Srisuwarn P, Sutharattanapong N, Disthabanchong S, Kantachuvesiri S, Kitiyakara C, Phakdeekitcharoen B. Incidence of De Novo Post-Transplant Malignancies in Thai Adult Kidney Transplant Recipients: A Single-Center, Population-Controlled, Retrospective Cohort Study at the Highest Volume Kidney Transplant Center in Thailand. Transplant International. 2024;37:11614.
https://doi.org/10.3389/ti.2024.11614
Imamura R, Nakazawa S, Yamanaka K, et al. Cumulative cancer incidence and mortality after kidney transplantation in Japan: a long-term multicenter cohort study. Cancer Med. 2021;10(7):2205- 2215.
https://doi.org/10.1002/cam4.3636
van de Wetering J, Roodnat JI, Hemke AC, Hoitsma AJ, Weimar W. Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study. Transplantation. 2010;90(12):1542-1546.
https://doi.org/10.1097/TP.0b013e3181ff1458
Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring HarbPerspect Med. 2013;3(7):a015677.
https://doi.org/10.1101/cshperspect.a015677
Li WH, et al. Malignancies after renal transplantation in Taiwan: a nationwide population-based study. Nephrol Dial Transpl. 2012;27:833-839.
https://doi.org/10.1093/ndt/gfr277
Cheung CY, et al. Malignancies after kidney transplantation: Hong Kong renal registry. Am J Transpl. 2012;12:3039-3046.
https://doi.org/10.1111/j.1600-6143.2012.04209.x
Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transpl. 2010;10:1889-1896.
https://doi.org/10.1111/j.1600-6143.2010.03181.x
Villeneuve PJ, et al. Cancer incidence among Canadian kidney transplant recipients. Am J Transpl. 2007;7:941-948.
https://doi.org/10.1111/j.1600-6143.2007.01736.x
Gioco R, Corona D, Agodi A, Privitera F, Barchitta M, Giaquinta A, et al. De novo cancer incidence and prognosis after kidney transplantation: a single center analysis. InTransplantation Proceedings. 2019; 51(9):2927-2930.
https://doi.org/10.1016/j.transproceed.2019.04.096
Horie K, Tsuchiya T, Iinuma K, et al. Risk factors and incidence of malignant neoplasms after kidney transplantation at a single institution in Japan. ClinExpNephrol. 2019;23(11):1323-1330.
https://doi.org/10.1007/s10157-019-01769-8
Malekshahi A, MortezaNejad HF, Taromsari MR. An evaluation of the current status of kidney transplant in terms of the type of receipt among Iranian patients. Ren Replace Ther. 2020; 6: 66.
https://doi.org/10.1186/s41100-020-00314-8
Simforoosh N, Basiri A, Tabibi A, Nadjafi-Semnani M. Living unrelated kidney transplant: does it prevent deceased-donor kidney transplant growth. ExpClin Transplant. 2019;17:250-3.
https://doi.org/10.6002/ect.MESOT2018.P110
Ardekani MS, Orlowski JM. Multiple listing in kidney transplant. Am J Kidney Dis. 2010;55(4):717-25.
https://doi.org/10.1053/j.ajkd.2009.11.022
Beladi Mousavi SS, Alemzadeh Ansari MJ, Parsi A, Kiani E. Reasons for Renal Donation among Living Unrelated Renal Donors in Khuzestan Province, Southwestern Iran. Int J Organ Transplant Med. 2013;4(1):21-4.
Simforoosh N, Soltani MH, Basiri A, Tabibi A, Gooran S, Sharifi SHH, et al. Evolution of laparoscopic live donor nephrectomy: a single-center experience with 1510 cases over 14 years. J Endourol. 2014;28(1):34-9.
https://doi.org/10.1089/end.2013.0460
Alatab S, Pourmand G. Implication of thymoglobulin in kidney transplant patients: review article. Tehran Univ Med J. 2015;73(8):545-53 [In Persian].
Park JM, Choi MG, Yang CW, Jung CK, Lee SK, Yoon AR, Kim YS, Chung IS. Increased incidence of gastric cancer in renal transplant recipients. J ClinGastroenterol. 2012;46(10):e87-91.
https://doi.org/10.1097/MCG.0b013e31825c0b3a
Ueda Y, Chiba T. Helicobacter pylori in solid-organ transplant recipient. CurrOpin Organ Transplant. 2008;13(6):586-91.
https://doi.org/10.1097/MOT.0b013e3283186b6a
Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F, Soerjomataram I. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 2017;67(1):51-64.
https://doi.org/10.3322/caac.21384
Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MR. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 2009;24(10):3225-31.
https://doi.org/10.1093/ndt/gfp331
Mohamed AH, Jeele MOO. Epidemiology of end-stage renal Disease in Mogadishu, Somalia: First Report at a Tertiary Care Hospital. Int J Gen Med. 2022;15:6259-6267.
https://doi.org/10.2147/IJGM.S375280
Workie SG, Zewale TA, Wassie GT, et al. Survival and predictors of mortality among chronic Kidney Disease patients on hemodialysis in Amhara region, Ethiopia, 2021. BMC Nephrol. 2022;23(1):1-9.
https://doi.org/10.1186/s12882-022-02825-4
Ameer OZ. Hypertension in chronic kidney disease: What lies behind the scene. Front Pharmacol. 2022 Oct 11;13:949260.
https://doi.org/10.3389/fphar.2022.949260
Okpechi IG, Ameh OI, Bello AK, Ronco P, Swanepoel CR, Kengne AP. Epide¬miology of histologically proven glomerulonephritis in Africa: a systematic review and Meta-analysis. PLoS ONE. 2016;11(3):e0152203.
https://doi.org/10.1371/journal.pone.0152203
Hughes OU, Stella A, Samuel E. Complications of Internal jugular catheters in haemodialysis patients at a kidney care center in Nigeria. J CliniNephrol. 2019;3:121-5.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.